Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma

Anubha Arora, Vijaya Raj Bhatt, Susanne Liewer, James O. Armitage, R. Gregory Bociek

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Brentuximab vedotin has emerged as a useful treatment option for relapsed or refractory Hodgkin's lymphoma; however, uncommon cases of anaphylactic reactions may require its permanent discontinuation. We report a 29-yr-old woman with refractory Hodgkin's lymphoma, who developed an anaphylactic reaction during the second dose of brentuximab vedotin. A 12-step desensitization protocol was followed; after premedicating with antihistaminic agents, methylprednisolone and montelukast, a total dose of 156mg of brentuximab vedotin (1.8mg/kg) was given as three infusions with increasing rate and concentration. Such desensitization protocol can allow safe administration of brentuximab vedotin and may have a broader applicability in managing hypersensitivity reactions with other monoclonal antibodies.

Original languageEnglish (US)
Pages (from-to)361-364
Number of pages4
JournalEuropean Journal of Haematology
Issue number4
StatePublished - Oct 1 2015


  • Anaphylaxis
  • Brentuximab vedotin
  • Desensitization
  • Hodgkin's lymphoma

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this